• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Roche Holding AG ADR

Roche Holding AG ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer

    FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer

  2. Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study

    Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study

  3. Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS™ (Ocrelizumab) Published in New England Journal of Medicine

    Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS™ (Ocrelizumab) Published in New England Journal of Medicine

  4. Betting Responsibly on Healthcare

    These funds offer thoughtful investments in healthcare, not tactical plays.

  5. A Push-Me, Pull-You Market

    Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...

  6. Low-Cost Exposure to U.S. Healthcare Firms

    This ETF holds a swath of large- and mid-cap U.S. healthcare companies.

  7. Roche Builds a Wide Moat With Dominant Oncology and Diagnostics Franchises

    Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.

  8. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.

  9. Ariel Goes Abroad

    Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.

  10. Why Retirees Should Consider Investing Abroad

    Readers say diversification and exposure to good companies call for looking beyond the U.S.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.